BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablets, Oral, 1 mg, Once daily, 14 days

DRUG

Placebo matching Dapagliflozin

Tablets, Oral, 0 mg, Once daily, 14 days

Trial Locations (12)

32127

Progressive Medical Research, Port Orange

32806

Compass Research Phase 1, Llc, Orlando

40509

Central Kentucky Research Associates, Inc., Lexington

49007

Jasper Clinic, Inc., Kalamazoo

57701

Regional Medical Clinic-Endocrinology, Rapid City

64106

Kansas City University Of Medicine And Biosciences, Kansas City

66212

Vince And Associates Clinical Research, Overland Park

70114

Louisiana Research Associates, Inc., New Orleans

75230

Dallas Diabetes & Endocrine Center, Dallas

90502

La Biomed Research Inst. At Harbor Ucla Med Ctr., Torrance

91911

Profil Institute For Clinical Research, Inc., Chula Vista

92161

Va San Diego Healthcare System, San Diego

Sponsors
All Listed Sponsors
collaborator

Astra Zeneca, Bristol-Myers Squibb

OTHER

lead

AstraZeneca

INDUSTRY